Emergent BioSolutions (NYSE:EBS) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $1.70 billion-$1.90 billion, compared to the consensus revenue estimate of $2 billion.
NYSE:EBS opened at $61.59 on Tuesday. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of 19.80 and a beta of 1.26. Emergent BioSolutions has a 52 week low of $60.70 and a 52 week high of $137.61. The company has a quick ratio of 2.30, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average of $78.89 and a 200 day moving average of $92.24.
Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, April 28th. The biopharmaceutical company reported $1.53 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.97 by $0.56. Emergent BioSolutions had a return on equity of 26.68% and a net margin of 12.50%. As a group, analysts expect that Emergent BioSolutions will post 6.94 EPS for the current year.
Several equities research analysts have weighed in on the company. Benchmark lowered their price target on Emergent BioSolutions from $150.00 to $120.00 and set a buy rating for the company in a report on Friday. Wells Fargo & Company cut shares of Emergent BioSolutions from an overweight rating to an equal weight rating and set a $110.00 target price for the company. in a research note on Friday, January 8th. Chardan Capital cut their price target on shares of Emergent BioSolutions from $112.00 to $92.00 and set a buy rating on the stock in a research note on Friday. Finally, Guggenheim dropped their price objective on shares of Emergent BioSolutions from $130.00 to $110.00 and set a buy rating on the stock in a report on Wednesday, April 14th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $103.43.
In related news, Director Sue Bailey sold 8,168 shares of the business's stock in a transaction on Thursday, March 4th. The shares were sold at an average price of $92.37, for a total transaction of $754,478.16. Following the completion of the transaction, the director now directly owns 24,427 shares in the company, valued at $2,256,321.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.10% of the company's stock.
Emergent BioSolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
Featured Story: What is Liquidity?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Most Active Stocks: Dollar Volume vs Share Volume7 Hotel Stocks Just Waiting For the Vaccine
Like any group of stocks related to travel and tourism, hotel stocks saw a steep drop in share prices in 2020. The leisure and hospitality sector that once had 15 million employees has lost 4 million jobs since February.
Many major cities will be feeling the ripple effects of the Covid-19 pandemic for years. However, there is ample evidence that shows the pandemic may be coming to an end. The number of new cases is dropping. The number of those getting vaccinated is rising. And even in the cities with the most restrictive mitigation measures, the slow process of reopening is beginning.
All of this can’t come fast enough for individuals who rely on the travel and tourism industry for their livelihood. Hotel chains had at least some revenue coming in the door. And when earnings season concludes, the more budget-friendly hotel chains may realize revenue that is 75% of its 2019 numbers. But that is not enough to bring the hotels to anywhere near full employment. Particularly with hotels that have bars and restaurants that have remained closed or open at limited capacity.
Many economists are optimistic that travel may begin to look more normal by the summer of this year. And the global economy may deliver 6.4% GDP growth this year. With that in mind, the hotel chains with the best fundamentals and the broadest footprint will be in the best position as the economy reopens.
View the "7 Hotel Stocks Just Waiting For the Vaccine"